Skye Bioscience Shows 18.1% vs 49.8% Weight Regain in Phase 2
Skye Bioscience (Nasdaq: SKYE) will present a late-breaking oral abstract…
Anaptys Announces Late‑Breaking Phase 2b Rosnilimab Data, 6‑Month Efficacy
Anaptys (NASDAQ: ANAB) announced that complete Phase 2b data for…